PSMC6

Summary

PSMC6 (proteasome 26S subunit, ATPase 6, HGNC:9553) is a protein-coding gene on chromosome 14q22.1, encoding 26S proteasome regulatory subunit 10B (P62333). Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. It is a common-essential gene (DepMap: required in 99.9% of cancer cell lines).

The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes one of the ATPase subunits, a member of the triple-A family of ATPases which have a chaperone-like activity. Pseudogenes have been identified on chromosomes 8 and 12.

Source: NCBI Gene 5706 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 24 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 99.9% of screened cell lines (common-essential)
• MANE Select transcript: NM_002806

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9553
Approved symbol	PSMC6
Name	proteasome 26S subunit, ATPase 6
Location	14q22.1
Locus type	gene with protein product
Status	Approved
Aliases	p42, RPT5
Ensembl gene	ENSG00000100519
Ensembl biotype	protein_coding
OMIM	602708
Entrez	5706

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 15 protein_coding, 6 retained_intron, 6 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000445930, ENST00000458604, ENST00000551328, ENST00000553798, ENST00000553899, ENST00000554044, ENST00000554952, ENST00000554956, ENST00000555175, ENST00000555339, ENST00000555887, ENST00000556813, ENST00000557085, ENST00000557240, ENST00000557517, ENST00000557557, ENST00000557632, ENST00000612399, ENST00000886147, ENST00000886148, ENST00000886149, ENST00000886150, ENST00000886151, ENST00000886152, ENST00000929612, ENST00000929614, ENST00000968040, ENST00000968041, ENST00000968042

RefSeq mRNA: 2 — MANE Select: NM_002806 NM_001366414, NM_002806

CCDS: CCDS9710

Canonical transcript exons

ENST00000445930 — 14 exons

Exon	Start	End
ENSE00000657452	52718229	52718352
ENSE00000657454	52718977	52719038
ENSE00000657456	52720861	52720981
ENSE00000657458	52721110	52721190
ENSE00001093466	52727499	52728590
ENSE00003567998	52708309	52708388
ENSE00003586046	52713881	52713968
ENSE00003588987	52708483	52708522
ENSE00003633761	52718081	52718142
ENSE00003677883	52711410	52711524
ENSE00003680470	52708764	52708816
ENSE00003693795	52711101	52711168
ENSE00003695961	52707200	52707304
ENSE00003784016	52723965	52724036

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 98.79.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 65.6621 / max 1240.9486, expressed in 1814 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
139618	59.6130	1814
139617	5.8891	1658
139621	0.1130	12
139620	0.0470	10

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
esophagus squamous epithelium	UBERON:0006920	98.79	gold quality
buccal mucosa cell	CL:0002336	98.37	gold quality
palpebral conjunctiva	UBERON:0001812	98.22	gold quality
epithelium of nasopharynx	UBERON:0001951	98.17	gold quality
amniotic fluid	UBERON:0000173	98.15	gold quality
tibia	UBERON:0000979	98.14	gold quality
germinal epithelium of ovary	UBERON:0001304	98.11	gold quality
visceral pleura	UBERON:0002401	98.10	gold quality
parietal pleura	UBERON:0002400	98.08	gold quality
mucosa of paranasal sinus	UBERON:0005030	97.89	gold quality
pleura	UBERON:0000977	97.85	gold quality
adrenal tissue	UBERON:0018303	97.85	gold quality
oral cavity	UBERON:0000167	97.78	gold quality
squamous epithelium	UBERON:0006914	97.71	gold quality
endometrium	UBERON:0001295	97.66	gold quality
epithelium of esophagus	UBERON:0001976	97.64	gold quality
gastrocnemius	UBERON:0001388	97.56	gold quality
calcaneal tendon	UBERON:0003701	97.53	gold quality
blood vessel layer	UBERON:0004797	97.46	gold quality
penis	UBERON:0000989	97.42	gold quality
muscle of leg	UBERON:0001383	97.42	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.42	gold quality
cartilage tissue	UBERON:0002418	97.32	gold quality
islet of Langerhans	UBERON:0000006	97.15	gold quality
lower esophagus mucosa	UBERON:0035834	97.11	gold quality
seminal vesicle	UBERON:0000998	97.09	gold quality
esophagus mucosa	UBERON:0002469	97.06	gold quality
rectum	UBERON:0001052	97.05	gold quality
muscle organ	UBERON:0001630	97.02	gold quality
endothelial cell	CL:0000115	97.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF2, CEBPB, FOS, HIF1A, JUN, TFAP2A, TP53

miRNA regulators (miRDB)

35 targeting PSMC6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-891B	99.59	69.81	1083
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-302B-5P	99.50	69.49	1857
HSA-MIR-302D-5P	99.50	69.34	1863
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-16-2-3P	99.29	70.60	1954
HSA-MIR-195-3P	99.29	70.61	1954
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-8065	99.19	70.38	1289
HSA-MIR-323B-3P	99.14	68.89	725

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 7)

• N protein of SARS Coronavirus interacts with the host cell proteasome subunit p42. (PMID:20478047)
• Evidence of a sex-specific association of PSMC6 genetic variants with subtypes of juvenile idiopathic arthritis. (PMID:24875235)
• Advanced oxidation protein products down-regulate the expression of calcium transport channels through p44/42 MAPK signaling mechanisms in the small intestinal epithelium. (PMID:25801217)
• Our results provide evidence on new T1DM-susceptible loci in the PSMA3, PSMA6 and PSMC6 proteasome genes and give a new insight into the T1DM pathogenesis (PMID:26661414)
• PSMC6 was differently expressed in melanosis coli tissues.PSMC6 expression was related to cell apoptosis. (PMID:30559147)
• PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model. (PMID:32017075)
• The Silence of PSMC6 Inhibits Cell Growth and Metastasis in Lung Adenocarcinoma. (PMID:34239933)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	psmc6	ENSDARG00000037038
mus_musculus	Psmc6	ENSMUSG00000021832
rattus_norvegicus	Psmc6	ENSRNOG00000007203
drosophila_melanogaster	Rpt4	FBGN0028685
drosophila_melanogaster	Rpt4R	FBGN0036224
caenorhabditis_elegans		WBGENE00004504

Paralogs (5): PSMC4 (ENSG00000013275), PSMC5 (ENSG00000087191), PSMC1 (ENSG00000100764), PSMC2 (ENSG00000161057), PSMC3 (ENSG00000165916)

Protein

Protein identifiers

26S proteasome regulatory subunit 10B — P62333 (reviewed: P62333)

Alternative names: 26S proteasome AAA-ATPase subunit RPT4, Proteasome 26S subunit ATPase 6, Proteasome subunit p42

All UniProt accessions (10): P62333, A0A087X2I1, H0YJC0, H0YJD2, H0YJE9, H0YJS8, H0YJT1, H0YJW2, H0YJX2, H0YJY8

UniProt curated annotations — full annotation on UniProt →

Function. Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMC6 belongs to the heterohexameric ring of AAA (ATPases associated with diverse cellular activities) proteins that unfolds ubiquitinated target proteins that are concurrently translocated into a proteolytic chamber and degraded into peptides.

Subunit / interactions. Component of the 19S proteasome regulatory particle complex. The 26S proteasome consists of a 20S core particle (CP) and two 19S regulatory subunits (RP). The regulatory particle is made of a lid composed of 9 subunits, a base containing 6 ATPases including PSMC6 and few additional components. Interacts with PAAF1.

Subcellular location. Cytoplasm. Nucleus.

Similarity. Belongs to the AAA ATPase family.

RefSeq proteins (2): NP_001353343, NP_002797* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003593	AAA+_ATPase	Domain
IPR003959	ATPase_AAA_core	Domain
IPR003960	ATPase_AAA_CS	Conserved_site
IPR012340	NA-bd_OB-fold	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR032501	Prot_ATP_ID_OB_2nd	Domain
IPR041569	AAA_lid_3	Domain
IPR050221	26S_Proteasome_ATPase	Family

Pfam: PF00004, PF16450, PF17862

UniProt features (37 total): helix 13, strand 12, turn 6, modified residue 3, chain 1, binding site 1, sequence conflict 1

Structure

Experimental structures (PDB)

74 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
8USB	ELECTRON MICROSCOPY	2.73
9PDL	ELECTRON MICROSCOPY	2.76
9E8I	ELECTRON MICROSCOPY	2.87
9BV3	ELECTRON MICROSCOPY	2.9
9E8H	ELECTRON MICROSCOPY	2.9
9PDI	ELECTRON MICROSCOPY	2.98
6MSB	ELECTRON MICROSCOPY	3
8CVT	ELECTRON MICROSCOPY	3
9E8G	ELECTRON MICROSCOPY	3.01
9PDN	ELECTRON MICROSCOPY	3.04
8USC	ELECTRON MICROSCOPY	3.1
9BV1	ELECTRON MICROSCOPY	3.1
9E8O	ELECTRON MICROSCOPY	3.1
9E8Q	ELECTRON MICROSCOPY	3.16
6MSD	ELECTRON MICROSCOPY	3.2
6MSK	ELECTRON MICROSCOPY	3.2
6MSE	ELECTRON MICROSCOPY	3.3
6MSJ	ELECTRON MICROSCOPY	3.3
9BW4	ELECTRON MICROSCOPY	3.3
9M2W	ELECTRON MICROSCOPY	3.31
8JRI	ELECTRON MICROSCOPY	3.4
9BV2	ELECTRON MICROSCOPY	3.4
9E8J	ELECTRON MICROSCOPY	3.47
5GJR	ELECTRON MICROSCOPY	3.5
6MSG	ELECTRON MICROSCOPY	3.5
9UG9	ELECTRON MICROSCOPY	3.5
9PF1	ELECTRON MICROSCOPY	3.57
9E8L	ELECTRON MICROSCOPY	3.59
5VFS	ELECTRON MICROSCOPY	3.6
6MSH	ELECTRON MICROSCOPY	3.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P62333-F1	86.98	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 174–181

Post-translational modifications (3): 72, 206, 244

Function

Pathways and Gene Ontology

Reactome pathways

68 pathways

ID	Pathway
R-HSA-1169091	Activation of NF-kappaB in B cells
R-HSA-1234176	Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
R-HSA-1236974	ER-Phagosome pathway
R-HSA-1236978	Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-174084	Autodegradation of Cdh1 by Cdh1:APC/C
R-HSA-174113	SCF-beta-TrCP mediated degradation of Emi1
R-HSA-174154	APC/C:Cdc20 mediated degradation of Securin
R-HSA-174178	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
R-HSA-174184	Cdc20:Phospho-APC/C mediated degradation of Cyclin A
R-HSA-180534	Vpu mediated degradation of CD4
R-HSA-180585	Vif-mediated degradation of APOBEC3G
R-HSA-187577	SCF(Skp2)-mediated degradation of p27/p21
R-HSA-195253	Degradation of beta-catenin by the destruction complex
R-HSA-202424	Downstream TCR signaling
R-HSA-211733	Regulation of activated PAK-2p34 by proteasome mediated degradation
R-HSA-2467813	Separation of Sister Chromatids
R-HSA-2871837	FCERI mediated NF-kB activation
R-HSA-349425	Autodegradation of the E3 ubiquitin ligase COP1
R-HSA-350562	Regulation of ornithine decarboxylase (ODC)
R-HSA-382556	ABC-family protein mediated transport
R-HSA-450408	AUF1 (hnRNP D0) binds and destabilizes mRNA
R-HSA-4608870	Asymmetric localization of PCP proteins
R-HSA-4641257	Degradation of AXIN
R-HSA-4641258	Degradation of DVL
R-HSA-5358346	Hedgehog ligand biogenesis
R-HSA-5362768	Hh mutants are degraded by ERAD
R-HSA-5607761	Dectin-1 mediated noncanonical NF-kB signaling
R-HSA-5607764	CLEC7A (Dectin-1) signaling
R-HSA-5610780	Degradation of GLI1 by the proteasome
R-HSA-5610783	Degradation of GLI2 by the proteasome

MSigDB gene sets: 350 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, RNGTGGGC_UNKNOWN, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITOSIS_EARLY_G1, REACTOME_INNATE_IMMUNE_SYSTEM, MORF_MBD4, MORF_RAB5A, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, KEGG_PROTEASOME, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION

GO Biological Process (5): ERAD pathway (GO:0036503), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), positive regulation of RNA polymerase II transcription preinitiation complex assembly (GO:0045899), positive regulation of inclusion body assembly (GO:0090261), positive regulation of proteasomal protein catabolic process (GO:1901800)

GO Molecular Function (7): ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), protein-macromolecule adaptor activity (GO:0030674), proteasome-activating activity (GO:0036402), identical protein binding (GO:0042802), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (11): proteasome complex (GO:0000502), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), proteasome regulatory particle, base subcomplex (GO:0008540), membrane (GO:0016020), inclusion body (GO:0016234), proteasome accessory complex (GO:0022624), cytosolic proteasome complex (GO:0031597), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-18 pathways:

Category	Pathways
Antigen processing-Cross presentation	2
APC/C-mediated degradation of cell cycle proteins	2
Host Interactions of HIV factors	2
Downstream signaling events of B Cell Receptor (BCR)	1
Cellular response to hypoxia	1
Regulation of APC/C activators between G1/S and early anaphase	1
APC/C:Cdc20 mediated degradation of mitotic proteins	1
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	1
Cyclin E associated events during G1/S transition	1
Cyclin A:Cdk2-associated events at S phase entry	1
Signaling by WNT	1
TCR signaling	1
Regulation of Apoptosis	1
Mitotic Anaphase	1
Fc epsilon receptor (FCERI) signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteasomal protein catabolic process	4
cellular anatomical structure	4
intracellular anatomical structure	3
ATP-dependent activity	2
protein binding	2
protein-containing complex	2
proteasome complex	2
response to endoplasmic reticulum stress	1
response to chemical	1
ubiquitin-dependent protein catabolic process	1
positive regulation of protein-containing complex assembly	1
regulation of RNA polymerase II transcription preinitiation complex assembly	1
RNA polymerase II preinitiation complex assembly	1
positive regulation of transcription initiation by RNA polymerase II	1
positive regulation of cellular component biogenesis	1
positive regulation of cellular component organization	1
inclusion body assembly	1
regulation of inclusion body assembly	1
positive regulation of protein catabolic process	1
regulation of proteasomal protein catabolic process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
molecular adaptor activity	1
polypeptide conformation or assembly isomerase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intracellular protein-containing complex	1
endopeptidase complex	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
proteasome regulatory particle	1
cytosol	1
extracellular vesicle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

371 interactions, top by confidence:

A	B	Type	Score
PSMC3	PSMC6	psi-mi:“MI:0915”(physical association)	0.950
PSMC6	PSMC3	psi-mi:“MI:0915”(physical association)	0.950
PSMC6	PSMC3	psi-mi:“MI:0407”(direct interaction)	0.950
PSMC3	PSMC6	psi-mi:“MI:0407”(direct interaction)	0.950
PSMC6	PSMC3	psi-mi:“MI:0914”(association)	0.950
PSMD9	PSMC6	psi-mi:“MI:0915”(physical association)	0.940
PSMC6	PSMD9	psi-mi:“MI:0915”(physical association)	0.940
PSMD9	PSMC3	psi-mi:“MI:0914”(association)	0.940
PSMC5	PSMC6	psi-mi:“MI:0915”(physical association)	0.940
PSMC1	PSMC6	psi-mi:“MI:0915”(physical association)	0.900
UCHL5	PSMD11	psi-mi:“MI:0914”(association)	0.840
PSMC4	PSMC6	psi-mi:“MI:0915”(physical association)	0.820
PSMD10	PSMD11	psi-mi:“MI:0914”(association)	0.800
CRK	PSMC6	psi-mi:“MI:0915”(physical association)	0.780

BioGRID (685): PSMC6 (Affinity Capture-MS), PSMC6 (Two-hybrid), PSMC6 (Two-hybrid), PSMD9 (Two-hybrid), SDCBP (Two-hybrid), CYB5R2 (Two-hybrid), CCDC146 (Two-hybrid), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS), PSMC6 (Affinity Capture-MS)

ESM2 similar proteins: A3CV35, A4G0S4, A6UQT3, A6VHR1, A7I8B8, A9A916, B8GGN4, O17071, O18413, O26824, O74445, O74894, P34124, P41836, P42811, P43686, P46502, P46507, P53549, P54775, P54778, P54814, P62194, P62195, P62196, P62197, P62198, P62333, P62334, P62335, Q01939, Q0W257, Q25544, Q2FQ56, Q2KIW6, Q3T030, Q4R7L3, Q54PJ1, Q63570, Q6LWR0

Diamond homologs: A0A061IR73, A0A7N9VSG0, A3CV35, A4G0S4, A6UQT3, A6VHR1, A7I8B8, A7YSY2, A9A916, B4U7U4, B9KXV3, C5A6P8, D4A2B7, D4GUJ7, G3GXG9, O05209, O14325, O15381, O18413, O26824, O28972, O43933, O57940, O60058, O67077, P03974, P23787, P25694, P32794, P41836, P46462, P46468, P46470, P54609, P54774, P54777, P54811, P54812, P54814, P55072

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PSMC6	“form complex”	“26S Proteasome”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 113 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Proteasome assembly	22	57.5×	1e-31
Regulation of activated PAK-2p34 by proteasome mediated degradation	16	57.1×	5e-23
Vpu mediated degradation of CD4	16	54.5×	7e-23
Autodegradation of the E3 ubiquitin ligase COP1	16	54.5×	7e-23
Ubiquitin-dependent degradation of Cyclin D	16	54.5×	7e-23
AUF1 (hnRNP D0) binds and destabilizes mRNA	17	54.1×	8e-24
Regulation of ornithine decarboxylase (ODC)	15	52.3×	1e-21
Cross-presentation of soluble exogenous antigens (endosomes)	16	52.1×	1e-22

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	21	12.6×	8e-15
ubiquitin-dependent protein catabolic process	9	7.7×	7e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	11
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1671 predictions. Top by Δscore:

Variant	Effect	Δscore
14:52707300:GGAGT:G	donor_gain	1.0000
14:52707301:GAGT:G	donor_gain	1.0000
14:52707301:GAGTG:G	donor_gain	1.0000
14:52707302:A:T	donor_gain	1.0000
14:52707303:GT:G	donor_gain	1.0000
14:52707305:G:GG	donor_gain	1.0000
14:52707305:GTGA:G	donor_loss	1.0000
14:52707306:TGAG:T	donor_loss	1.0000
14:52707307:GAGTG:G	donor_loss	1.0000
14:52708307:A:AG	acceptor_gain	1.0000
14:52708308:G:GA	acceptor_gain	1.0000
14:52708308:GT:G	acceptor_gain	1.0000
14:52708308:GTA:G	acceptor_gain	1.0000
14:52708386:CAGG:C	donor_loss	1.0000
14:52708387:AG:A	donor_loss	1.0000
14:52708389:G:A	donor_loss	1.0000
14:52708390:T:G	donor_loss	1.0000
14:52708478:CTTA:C	acceptor_loss	1.0000
14:52708479:TTAG:T	acceptor_loss	1.0000
14:52708480:TAGAT:T	acceptor_loss	1.0000
14:52708481:A:AG	acceptor_gain	1.0000
14:52708481:AGA:A	acceptor_loss	1.0000
14:52708482:G:A	acceptor_loss	1.0000
14:52708482:G:GG	acceptor_gain	1.0000
14:52708482:GATC:G	acceptor_gain	1.0000
14:52708521:AT:A	donor_gain	1.0000
14:52708523:G:GA	donor_loss	1.0000
14:52708523:G:GG	donor_gain	1.0000
14:52708524:T:G	donor_loss	1.0000
14:52708762:A:AG	acceptor_gain	1.0000

AlphaMissense

2554 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:52708383:G:A	G54R	1.000
14:52708383:G:C	G54R	1.000
14:52708383:G:T	G54W	1.000
14:52708384:G:A	G54E	1.000
14:52708384:G:T	G54V	1.000
14:52708489:G:C	G58R	1.000
14:52708490:G:A	G58D	1.000
14:52708770:T:A	V71D	1.000
14:52708784:G:A	G76R	1.000
14:52708784:G:C	G76R	1.000
14:52708785:G:A	G76E	1.000
14:52708797:T:A	V80D	1.000
14:52711135:T:A	V98D	1.000
14:52711138:C:A	A99D	1.000
14:52711141:T:G	L100W	1.000
14:52711156:T:C	L105P	1.000
14:52711439:T:A	V119D	1.000
14:52711490:G:A	G136E	1.000
14:52711492:G:A	G137R	1.000
14:52711492:G:C	G137R	1.000
14:52711493:G:A	G137E	1.000
14:52711496:T:C	L138P	1.000
14:52713885:T:A	I149K	1.000
14:52713897:T:C	L153P	1.000
14:52713914:T:C	F159L	1.000
14:52713915:T:C	F159S	1.000
14:52713916:T:A	F159L	1.000
14:52713916:T:G	F159L	1.000
14:52713927:G:T	G163V	1.000
14:52713930:T:A	I164K	1.000

dbSNP variants (sampled 300 via entrez): RS1000077396 (14:52710716 G>A), RS1000367724 (14:52717302 T>C), RS1000402885 (14:52725205 G>C), RS1000424289 (14:52724540 A>G), RS1000455248 (14:52724868 G>A), RS1000532591 (14:52713386 A>G), RS1000604726 (14:52713144 C>A), RS1000978458 (14:52727729 A>C,T), RS1001050942 (14:52712690 T>G), RS1001071002 (14:52706070 G>A,C,T), RS1001078675 (14:52712298 A>G), RS1001220542 (14:52707029 G>A,T), RS1001343293 (14:52719310 G>A,C), RS1001436994 (14:52706300 C>T), RS1001499010 (14:52720622 G>A,T)

Disease associations

OMIM: gene MIM:602708 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001942_15	Prostate cancer	2.000000e-14

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2364701 (PROTEIN COMPLEX), CHEMBL3831206 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 25,628 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL325041	BORTEZOMIB	4	13,120
CHEMBL451887	CARFILZOMIB	4	12,508

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

64 potent at pChembl≥5 of 67 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.62	IC50	2.4	nM	BORTEZOMIB
8.59	IC50	2.56	nM	BORTEZOMIB
8.57	IC50	2.7	nM	CHEMBL3237863
8.47	IC50	3.4	nM	CHEMBL6143686
8.41	IC50	3.9	nM	CHEMBL3237862
8.39	IC50	4.1	nM	CHEMBL3237864
8.39	IC50	4.1	nM	CHEMBL3237867
8.32	IC50	4.8	nM	CHEMBL3237873
8.29	IC50	5.1	nM	CHEMBL3237865
8.24	IC50	5.7	nM	CHEMBL3237866
8.24	IC50	5.7	nM	CHEMBL3237860
8.23	IC50	5.9	nM	CHEMBL3237868
8.15	IC50	7	nM	BORTEZOMIB
8.15	IC50	7.1	nM	CHEMBL3237870
8.15	IC50	7.14	nM	BORTEZOMIB
8.12	IC50	7.5	nM	CHEMBL3237871
8.11	IC50	7.7	nM	CHEMBL3237874
8.11	IC50	7.8	nM	CHEMBL3237869
8.07	IC50	8.6	nM	CARFILZOMIB
7.54	IC50	29	nM	CHEMBL3237861
7.34	IC50	46	nM	CHEMBL3237867
7.27	IC50	54	nM	CHEMBL3237872
7.12	IC50	75	nM	CHEMBL3237865
7.12	IC50	76	nM	CHEMBL3237866
6.96	IC50	110	nM	CHEMBL3262766
6.92	IC50	120	nM	CHEMBL3237864
6.92	IC50	120	nM	BORTEZOMIB
6.89	IC50	130	nM	CHEMBL3237869
6.85	IC50	140	nM	CHEMBL3237862
6.82	IC50	150	nM	CHEMBL3237863
6.79	Kd	164.1	nM	CHEMBL5653589
6.79	ED50	164.1	nM	CHEMBL5653589
6.77	IC50	170	nM	CHEMBL3237873
6.77	IC50	170	nM	CHEMBL3262765
6.72	IC50	190	nM	CHEMBL3262758
6.68	IC50	210	nM	CHEMBL3237870
6.66	IC50	220	nM	CHEMBL3262756
6.60	IC50	250	nM	CHEMBL3237868
6.47	IC50	340	nM	CHEMBL3262752
6.47	IC50	340	nM	CHEMBL3262755
6.44	IC50	360	nM	CHEMBL3262757
6.42	IC50	380	nM	CHEMBL3262754
6.36	IC50	440	nM	CHEMBL3262753
6.30	IC50	500	nM	CHEMBL3237872
6.20	IC50	630	nM	CHEMBL3262762
6.02	IC50	950	nM	CHEMBL3262761
6.00	IC50	1000	nM	CHEMBL3237871
5.96	IC50	1100	nM	CHEMBL3237862
5.85	IC50	1400	nM	BELACTOSIN A
5.84	IC50	1440	nM	BELACTOSIN A

PubChem BioAssay actives

61 with measured affinity, of 137 total; 33 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Bortezomib	1985684: Inhibition of 26S proteasome (unknown origin)	ic50	0.0024	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0027	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[3-phenylmethoxy-2-(phenylmethoxymethyl)propyl]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0039	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[5-phenylmethoxy-4-(phenylmethoxymethyl)pentyl]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0041	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[5-phenylmethoxy-4-(phenylmethoxymethyl)pentyl]pentanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0041	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-(4-phenylmethoxybutyl)butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0048	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[3-phenylmethoxy-2-(phenylmethoxymethyl)propyl]pentanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0051	uM
(2S)-2-acetamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]pentanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0057	uM
benzyl N-[(2S)-1-[[(2R)-1-[(1R,2S)-2-[[(2R,3S)-3-[(2S)-butan-2-yl]-4-oxooxetane-2-carbonyl]amino]cyclopropyl]-4-phenylbutan-2-yl]amino]-1-oxopropan-2-yl]carbamate	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0057	uM
(2S)-2-[(2,5-dichlorobenzoyl)amino]-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0059	uM
(2S)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]-2-(pyrazine-2-carbonylamino)butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0071	uM
(2S)-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]-2-[(6-phenylpyridine-2-carbonyl)amino]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0075	uM
[(1R)-1-[[(2S)-2-acetamido-4-oxo-4-[[3-phenylmethoxy-2-(phenylmethoxymethyl)propyl]amino]butanoyl]amino]-3-methylbutyl]boronic acid	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0077	uM
(2S)-2-benzamido-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0078	uM
Carfilzomib	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.0086	uM
(2R,3S)-3-[(2S)-butan-2-yl]-4-oxo-N-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]oxetane-2-carboxamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0290	uM
(2S)-2-acetamido-N’-methyl-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]butanediamide	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	0.0540	uM
N-[(1R)-3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]naphthalene-2-carboxamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.1100	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149120: Binding affinity to human PSMC6 incubated for 45 mins by Kinobead based pull down assay	kd	0.1641	uM
N-[(1R)-3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]-4-(trifluoromethyl)benzamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.1700	uM
N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]naphthalene-2-carboxamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.1900	uM
N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]-4-(trifluoromethyl)benzamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.2200	uM
N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]pyridine-3-carboxamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.3400	uM
4-methoxy-N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]benzamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.3400	uM
4-cyano-N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]benzamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.3600	uM
4-fluoro-N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]benzamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.3800	uM
N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]benzamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.4400	uM
N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]oxane-4-carboxamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.6300	uM
N-[3-[[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-oxo-1-phenylpropyl]thiophene-2-carboxamide	1141825: Inhibition of chymotrypsin-like enzyme activity of purified human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorescence method	ic50	0.9500	uM
(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-[(1S,2S)-2-[[(2R,3S)-3-[(2S)-butan-2-yl]-4-oxooxetane-2-carbonyl]amino]cyclopropyl]propanoic acid	1128229: Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-AMC as substrate	ic50	1.4000	uM
(2S)-2-acetamido-N-[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]-N’-[4-phenylmethoxy-3-(phenylmethoxymethyl)butyl]butanediamide	1152964: Inhibition of chymotrypsin-like of human 20S proteasome using chromophoric Suc-LLVY-AMC as substrate after 60 mins by fluorescence assay	ic50	2.3000	uM
N-[3-(2-oxo-1,3,4-oxathiazol-5-yl)phenyl]acetamide	1137840: Inhibition of chymotrypsin-like activity of 26S proteasome in intact human Karpas 1106p cells assessed as substrate hydrolysis using Suc-LLVY-(D)-aminoluciferin as substrate after 3 hrs by cell-based Proteasome-Glo assay	ec50	4.2000	uM
(2S)-2-acetamido-N-[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]-N’-(4-phenylmethoxybutyl)butanediamide	1152964: Inhibition of chymotrypsin-like of human 20S proteasome using chromophoric Suc-LLVY-AMC as substrate after 60 mins by fluorescence assay	ic50	5.7000	uM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects binding, increases reaction, decreases expression, affects cotreatment, increases abundance (+1 more)	4
Valproic Acid	decreases expression, decreases methylation, affects cotreatment, increases expression	4
Air Pollutants	increases oxidation, affects expression, decreases expression, affects cotreatment, increases abundance	3
Arsenic	increases methylation, affects cotreatment, increases abundance, increases expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance, affects expression	2
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
bisphenol A	decreases expression	1
nobiletin	decreases expression, decreases reaction	1
sodium arsenate	decreases expression, decreases reaction	1
decabromobiphenyl ether	decreases expression	1
kojic acid	decreases expression	1
cobaltous chloride	increases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	increases expression	1
2-palmitoylglycerol	increases expression	1
clothianidin	decreases expression	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
elesclomol	increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	increases expression	1

ChEMBL screening assays

27 unique, capped per target: 27 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3222879	Binding	Inhibition of human 20S proteasome using Suc-LLVY-AMC as substrate preincubated for 30 mins followed by substrate addition measured after 90 mins by fluorescence assay	Oxathiazole-2-one derivative of bortezomib: Synthesis, stability and proteasome inhibition activity — Medchemcomm

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.